One of the biggest cannabis U.S. operators publicly trading in a Canadian exchange provided shareholders with an update on their sales for the month of March in the state of Arizona.

On Tuesday (April 3) MPX Bioceutical Corporation (CSE:MPX; OTC:MPXEF) issued a statement revealing to investors the company reached a benchmark of US$4 million, representing roughly C$5.2 million in sales for the month of March alone.

Beth Stavola, COO, and president of MPX’s U.S. operations said in the statement that Arizona is a great state for the company. She added the company is satisfied with the regulations from the Arizona Department of Health Services (AZDHS).

“The Arizona program is well-regulated by AZDHS, the patient count continues to grow, the supply and cost of flower and trim for re-sale and concentrate production is excellent and, while the Phoenix area market is increasingly competitive, retail prices and margins remain attractive,” Stavola said.

MPX holds a variety of assets in the U.S. market, but this year the company announced an expansion in Arizona by acquiring the assets of the membership units of ABACA, Ambary, Tarmac Manufacturing, and Tower Management Holdings.

The company reported sales progression after expanding its footprint in Arizona

During a recent update call with analysts and investors from MPX, Stavola revealed the company’s market share in Arizona amounted to roughly seven or eight percent.

After revealing its expansion in Arizona chairman, president, and CEO of MPX Scott Boyes said the new acquisitions had “recorded trailing 12-month revenues of US$15 million and EBITDA of approximately US$3.5 million.”

Instead of waiting for the pursuit of an LP status, Boyes told the Investing News Network (INN) last year MPX would instead invest in legal cannabis states in the U.S. market.

The company now holds three operating dispensaries, two cultivation and two concentrate production facilities in the Greater Phoenix area.

Investor takeaway

Canaccord Genuity began its official coverage of MPX this year. In March analyst Matt Bottomley issued his first full-length report on the company’s development, starting his coverage with a “Speculative Buy” rating and a price target of C$1.15.

“We believe investing in vertically integrated operations is of particular importance, as owning retail distribution channels both increases operating margins and protects against wholesale pricing pressures and cultivation commoditization,” Bottomley wrote.

“We believe successful branding strategies and retail distribution will eventually determine industry winners,” he added.

In his research, the analyst noted MPX’s value comes from already owning branded dispensaries, holding award-winning brands and leading the medical market in Arizona.

According to Bottomley, the speculative rating was given due to the MPX’s high growth profile and the continued lack of US federal support.

After the markets closed on Tuesday, MPX’s share price was valued at C$0.70, representing no percentage change from Monday’s trading period.

So far in, 2018 the company’s stock on the Canadian Securities Exchange (CSE) has tumbled 37.50 percent, representing a C$0.42 loss.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today its participation in the following investor conferences:

  • Needham 2nd Annual Virtual Cannabis Conference – March 3 rd , 2021 – Management will participate in virtual one-on-one meetings.
  • 33rd Annual Roth Conference – March 15 th -17 th , 2021 – Charlie Bachtell, CEO and Co-Founder, will participate in a Fireside Chat and management will later participate in virtual one-on-one meetings on April 7 th .
  • Stifel Multi-Sector Conference – April 21 st , 2021 – Management will participate in virtual one-on-one meetings.

About Cresco Labs

Keep reading... Show less

Green Thumb Industries, a leading cannabis consumer packaged goods company and owner of Rise™ Dispensaries, is expanding key partnerships and creating scholarships earmarked for those from communities most impacted by the war on drugs as part of its corporate social responsibility program. The scholarships will be granted to a total of four students for programs at the Cleveland School of Cannabis in Ohio and Olive-Harvey College in Illinois. Additionally, Green Thumb will continue its support of Cabrini Green Legal Aid and partner with the North Lawndale Employment Network in Chicago as part of ongoing collaborations that include financial support, volunteerism and awareness initiatives.

Building on the foundation of Green Thumb’s LEAP initiative, which provided pro-bono support for social equity license applicants in Illinois and which will soon offer business incubator resources to newly awarded social equity entrepreneurs, these impactful partnerships mark a critical next step in prioritizing diversity, equity, and inclusion in the cannabis industry.

Keep reading... Show less

All five flavours of the Company’s KOIOS™ nootropic beverage product are now being carried by Jensen’s, a regional supermarket chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. This placement of KOIOS™ follows several other recent placements of the Company’s beverage products in regional supermarket chains across the United States as part of a strategy to passively build market share in specific geographical areas.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that the full range of five flavours of its KOIOS ™ nootropic beverages can now be purchased at all grocery stores operated by Jensen’s Foods (“Jensen’s”), a long-established family-owned grocery chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. In a press release dated February 19, 2021 the Company announced another chain-wide placement of KOIOS ™ nootropic beverages on the west coast of the United States with Market of Choice in Oregon. With this placement of KOIOS ™ in Jensen’s supermarkets, the Company’s beverage products are now carried in approximately 180 retail stores on the west coast, out of a total of more than 4,000 retail stores nationwide.

Keep reading... Show less

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less